Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Motif Bio: Latest data burnishes the credentials of new antibiotic

iclaprim is being developed to treat serious skin infections
researcher using microscope
Much of the latest data comes from two phase III clinical trials carried out by Motif

Data will be presented at a conference that suggests Motif Bio Plc’s (LON:MTFB) next-generation antibiotic has a number of advantages over the current crop of drugs designed to combat infection.

A review of the two phase III studies carried out on iclaprim showed there were fewer adverse events among diabetic patients taking the drug than those on the standard of care, a treatment called Vancomycin.

Drilling down, the statistical read-out showed no patients in the iclaprim group developed kidney injury, compared with three on Vancomycin.

Additionally, only 3.6% of the iclaprim group had to be taken off the drug compared with 10% receiving the standard of care.

Separately, surveillance data from work performed in the lab has confirmed iclaprim has the potential to work against a wide variety of Gram-positive bacteria, including drug-resistant strains.

Need for new antibiotics

"Given the worldwide crisis in antibiotic resistance, there remains a major need for new antibiotic treatments,” said David Huang, Motif’s chief medical officer.

“We have shown comprehensive data indicating that iclaprim has potent activity against a wide variety of Gram-positive bacteria, including MRSA that cause severe skin infections.”

The latest statistical update will be presented later Wednesday at an industry conference being held in Lisbon.

After successfully negotiating two phase III clinical trials a new drug submission has been made to the US Food & Drug Administration, which will come back with a decision on iclaprim in February next year.

Initially, the antibiotic will be used to treat acute bacterial skin and skin structure infections.

View full MTFB profile View Profile

Motif Bio Plc Timeline

Related Articles

1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use